PL
AUTL

Perpetual Ltd’s Autolus Therapeutics AUTL Stock Holding History

Perpetual Ltd’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-481,081
Closed -$784K – 419
2025
Q3 		$784K Sell
481,081
-348,009
-42% -$680K 0.01% 281
2025
Q2 		$1.89M Sell
829,090
-394,653
-32% -$653K 0.02% 202
2025
Q1 		$1.9M Sell
1,223,743
-55,877
-4% -$113K 0.02% 206
2024
Q4 		$3.01M Sell
1,279,620
-319,632
-20% -$1.08M 0.04% 164
2024
Q3 		$5.81M Sell
1,599,252
-801,160
-33% -$3.2M 0.06% 146
2024
Q2 		$8.35M Buy
2,400,412
+165,897
+7% +$716K 0.09% 134
2024
Q1 		$14.3M Buy
2,234,515
+169,784
+8% +$1.06M 0.14% 118
2023
Q4 		$13.3M Buy
2,064,731
+91,683
+5% +$350K 0.14% 113
2023
Q3 		$4.6M Sell
1,973,048
-23,307
-1% -$66.4K 0.05% 170
2023
Q2 		$4.75M Buy
1,996,355
+138,264
+7% +$328K 0.04% 186
2023
Q1 		$3.42M Buy
+1,858,091
New +$3.63M 0.03% 209

Other funds holding AUTL

MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Perpetual Ltd's AUTL Position: Q4 2025 in Review

Perpetual Ltd sold out of Autolus Therapeutics (AUTL) in Q4 2025, closing a stake of 481,081 shares — an estimated $784K sold.

Perpetual Ltd first reported a position in AUTL in Q1 2023 and held it in 11 quarters. The position peaked at $14.3M in Q1 2024. 89 funds tracked by Wall St. Rank hold AUTL as of Q4 2025.

  • Perpetual Ltd reported no remaining Autolus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Perpetual Ltd sold 481,081 Autolus Therapeutics shares in Q4 2025, an estimated $784K.
  • Perpetual Ltd first reported a position in Autolus Therapeutics in Q1 2023 and held it in 11 quarters.
  • Perpetual Ltd's Autolus Therapeutics position peaked at $14.3M in Q1 2024.
  • 89 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2025.

Based on Perpetual Ltd's 13F filing for Q4 2025, filed 20 Jan 2026.